Indian study shows drug-resistant fungus turning more deadly, spreading globally
New Delhi, Dec 30
The drug-resistant fungal species Candida auris is turning more deadly and is also spreading globally, according to a study led by Indian researchers.
Candida auris is a multidrug-resistant fungal pathogen that has a unique ability to grow and persist on human skin.
The study by researchers from the Vallabhbhai Patel Chest Institute, University of Delhi, in collaboration with the team at the National Institutes of Health in the US, showed that invasive fungal infections are spreading across the globe, and gaining in virulence, affecting about 6.5 million people per year.
These infections are frequently associated with high mortality rates, often exceeding 50 per cent, even with antifungal therapy.
"C. auris has developed wily cellular strategies to survive, including morphogenesis in its ability to switch from yeast growth to filament-driven spread, as well as forming multicellular aggregates, and also switching its phenotypic genetic expression in response to its changing environment," said the team in the paper published in the journal Microbiology and Molecular Biology Reviews.
The fungus is also extremely successful in colonising human skin, with the molecular evidence showing so far that the proteins of the cell wall attach like a kind of glue to mammalian cells -- and even non-living surfaces.
Long-term skin colonisation by C. auris is a significant medical concern because colonised patients may facilitate inter- and intra-hospital transmission of C. auris to other patients.
Furthermore, C. auris-colonised patients are at risk of developing more serious systemic infections, the team said.
While the host develops mechanisms to battle C. auris, the science so far indicates the germ can develop proactive ways to evade the immune response.
Diagnostics also remain a challenge, since most conventional lab tests lead to misidentification as other related yeasts, which delays and complicates treatment.
But awareness of the burden of this relatively new scourge is growing -- and research is now proliferating to catch up to clinical needs.
"Taken together, these data underscore the need to develop novel antifungal agents with broad-spectrum activity against human fungal pathogens, to improve diagnostic tests, and to develop immune- and vaccine-based adjunct modalities for the treatment of high-risk patients," the researchers write.
The study also called for efforts to raise awareness about fungal disease through developing better surveillance mechanisms, especially in resource-poor countries.
— IANS
Reader Comments
Scary stuff. After COVID, we really need to invest more in public health research and surveillance. The article mentions resource-poor countries - we must ensure our primary health centres are equipped to identify such threats early. Jai Hind.
Working in a clinic, the misdiagnosis part is a huge concern. If labs can't identify it correctly, how can we treat it? More funding for diagnostic tools is non-negotiable. This is a global problem that needs a global response.
Proud of our scientists at Delhi University! 🧬 This kind of collaborative research with US institutes is exactly what we need. But awareness is key - how many regular people have even heard of Candida auris? Public health messaging needs to improve.
While the research is important, I hope the findings lead to actionable policy. We have brilliant minds in India, but often the implementation fails. The government should prioritize this and allocate funds for surveillance and new drug development.
The fungus "developing wily strategies" sounds like a sci-fi movie. 😟 It's a reminder that we're in a constant battle with microbes. Basic hygiene in hospitals and public places has never been more important. Let's not get complacent.
We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.